580 related articles for article (PubMed ID: 22416777)
1. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
Gryder BE; Sodji QH; Oyelere AK
Future Med Chem; 2012 Mar; 4(4):505-24. PubMed ID: 22416777
[TBL] [Abstract][Full Text] [Related]
2. New and emerging HDAC inhibitors for cancer treatment.
West AC; Johnstone RW
J Clin Invest; 2014 Jan; 124(1):30-9. PubMed ID: 24382387
[TBL] [Abstract][Full Text] [Related]
3. Selective Histone Deacetylase Inhibitors with Anticancer Activity.
Ma N; Luo Y; Wang Y; Liao C; Ye WC; Jiang S
Curr Top Med Chem; 2016; 16(4):415-26. PubMed ID: 26268343
[TBL] [Abstract][Full Text] [Related]
4. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
Thurn KT; Thomas S; Moore A; Munster PN
Future Oncol; 2011 Feb; 7(2):263-83. PubMed ID: 21345145
[TBL] [Abstract][Full Text] [Related]
5. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
6. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
Pojani E; Barlocco D
Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
[TBL] [Abstract][Full Text] [Related]
9. HDAC Inhibitors as Novel Anti-Cancer Therapeutics.
De Souza C; Chatterji BP
Recent Pat Anticancer Drug Discov; 2015; 10(2):145-62. PubMed ID: 25782916
[TBL] [Abstract][Full Text] [Related]
10. Isoform-selective histone deacetylase inhibitors.
Bieliauskas AV; Pflum MK
Chem Soc Rev; 2008 Jul; 37(7):1402-13. PubMed ID: 18568166
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
[TBL] [Abstract][Full Text] [Related]
12. Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics.
Tasneem S; Alam MM; Amir M; Akhter M; Parvez S; Verma G; Nainwal LM; Equbal A; Anwer T; Shaquiquzzaman M
Mini Rev Med Chem; 2022; 22(12):1648-1706. PubMed ID: 34939540
[TBL] [Abstract][Full Text] [Related]
13. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitor-based therapies: can we interpret the code?
New M; Olzscha H; La Thangue NB
Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
[TBL] [Abstract][Full Text] [Related]
15. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
Choi SE; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
Giannini G; Cabri W; Fattorusso C; Rodriquez M
Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
[TBL] [Abstract][Full Text] [Related]
17. Influence of natural and synthetic histone deacetylase inhibitors on chromatin.
Licciardi PV; Kwa FA; Ververis K; Di Costanzo N; Balcerczyk A; Tang ML; El-Osta A; Karagiannis TC
Antioxid Redox Signal; 2012 Jul; 17(2):340-54. PubMed ID: 22229817
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
19. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat.
Zagni C; Floresta G; Monciino G; Rescifina A
Med Res Rev; 2017 Nov; 37(6):1373-1428. PubMed ID: 28181261
[TBL] [Abstract][Full Text] [Related]
20. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]